Banked Primary Progenitor Cells for Allogeneic Intervertebral Disc (IVD) Therapy: Preclinical Qualification and...

Area of Science:

• Regenerative Medicine
• Cell Therapy
• Biotechnology

Background:

• Biological products offer new therapeutic options for intervertebral disc (IVD) degeneration and lower back pain.
• Clinical application of autologous and allogeneic cell therapies for IVD repair is growing.
• Manufacturing process design significantly impacts clinical outcomes in cell therapy.

Purpose of the Study:

• To preclinically qualify cryopreserved FE002-Disc cells for IVD repair/regeneration.
• To assess the safety, chondrogenic potential, and resistance to stimuli of these cells.
• To evaluate the delivery potential of these cells as spheroids and optimize their culture and storage.

Main Methods:

• Conducted safety assays (soft agar, β-galactosidase, telomerase activity) and functionality tests (hypoxic/inflammatory challenge).
• Evaluated chondrogenic potential via collagen II and glycosaminoglycan (GAG) synthesis in spheroids.
• Investigated process parameters including induction medium, hypoxic incubation, and lyophilization.

Main Results:

• FE002-Disc cells demonstrated high sustainability in cell banking, with finite in vitro lifespan.
• Spheroids exhibited strong collagen II and GAG synthesis after 3-week chondrogenic induction.
• Optimal conditions (10 nM dexamethasone, 2% O2 incubation) were defined for spheroid production.

Conclusions:

• FE002-Disc progenitor cells are qualified for preclinical investigation based on safety, quality, and functionality.
• Defined processes for preparing IVD spheroids from an allogeneic human cell source were established.
• Robust product components and optimized manufacturing are crucial for high-quality cell-based formulations.